Breaks Categories: News

ThursdayDec 30, 2021 10:33 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Tribe Public’s Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and General Manager of BayMedica, Shane Johnson, and VP of Commercial Operations Chris Meiering will present at Tribe Public’s upcoming webinar presentation and Q&A event. The event, titled “Addressing the Increasing Demand for Rare Cannabinoids,” is slated to begin at 8 a.m. Pacific/11.a.m. Eastern on Jan. 6, 2022. Interested parties should visit https://ibn.fm/Qxj0G to register to join the complimentary, ZOOM webinar-based event. Once registered, participants may begin forwarding their questions for InMed and BayMedica’s management to…

Continue Reading

WednesdayDec 22, 2021 11:08 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with Maya. The two companies plan to co-develop a novel digital therapeutics (DTx) platform, which would allow Mydecine to enhance treatment effectiveness by pairing the DTx with its existing digital health platform, Mindleap Health, alongside its medication-based treatments to create a trifecta approach. “The technology integration of the two software platforms is aimed at enhancing Mindleap’s medical capabilities to more quickly and efficiently develop a personalized prescription-based digital…

Continue Reading

MondayDec 20, 2021 11:41 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces General Meeting Voting, Publication of Key Article on CBN as Possible Glaucoma Treatment

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, held its general meeting on Dec. 17, 2021, and approved the election of all director nominees. Those elected will hold office until the next annual shareholder meeting or until their successors are elected or appointed. The company also noted that all of the matters outlined for consideration and approval in InMed’s notice of meeting and management information circular were approved. In addition, the company announced that an article discussing cannabinol (“CBN”) as a potential treatment option for glaucoma has been published in a peer-reviewed journal.…

Continue Reading

FridayDec 17, 2021 2:27 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Advancing MYCO-001 to Bring Safer, More Effective Smoking Cessation Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat Nicotine Dependance,” covers Mydecine’s partnership with Dr. Matthew Johnson and Johns Hopkins University to advance its lead drug candidate MYCO-001 as a smoking cessation treatment. The company’s phase 2/3 smoking cessation clinical trial, set to launch in early 2022, builds from Dr. Johnson’s previous research…

Continue Reading

TuesdayDec 14, 2021 12:28 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Strategic CMO Appointment of Dr. Doron Sagman

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, today announced its appointment of Doron Sagman, MD, FRCPC, as the company's new chief medical officer ("CMO"). Per the update, Dr. Joel Raskin, who was acting CMO, will transition into an advisory role for MINDCURE. As CMO, Dr. Sagman will play a key role in furthering MINDCURE'S mission to reinvent the mental health care model for patients and practitioners and advancing psychedelic-assisted therapy into common and accepted care. “Dr. Sagman's distinguished career in both mental health and the pharmaceutical industries…

Continue Reading

FridayDec 10, 2021 12:25 pm

BioMedNewsBreaks – Mind Medicine (‘MindMed’) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) Engages with FDA for Development of the ‘MSMS’

Mind Medicine (“MindMed”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, recently met with the United States Food and Drug Administration (“FDA”) Center for Devices and Radiological Health (“CDRH”) with consultation from the Center for Drug Evaluation and Research (“CDER”). The device pre-submission meeting that took place on Oct. 25, 2021, was concerning several key points for ongoing development of the MindMed Session Monitoring System (“MSMS”). MindMed presented the FDA with a working Indications for Use (“IFU”) statement and a development roadmap, which describe technology and infrastructure for the collection of precise, multimodal, multivalent data…

Continue Reading

FridayDec 10, 2021 11:13 am

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular Diagnostics, a peer-reviewed international medical journal that has an impact factor of 5.2. “We are very pleased with the publication of our technical paper on CDA cancer detection technology by a peer-reviewed international journal in the field of medicine,” said Dr. Chris Yu, AnPac Bio’s…

Continue Reading

ThursdayDec 09, 2021 8:30 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Establishment of Regulatory Advisory Board, Strategic Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has formed a regulatory advisory board (“RAB”) and has appointed Joga Gobburu, B.Pharm (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. Dr. Gobburu is a world-recognized scientific leader in pharmacometrics and a professor at the School of Pharmacy and the School of Medicine at the University of Maryland. Dr. Melnyk is an expert in manufacturing and regulatory requirements for pharmaceutical and medical device development. She is the senior regulatory…

Continue Reading

WednesdayDec 08, 2021 3:48 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Secures Medical Device Certification for IoT-Powered Dry Herb Inhaler, Software

RYAH Group (CSE: RYAH) today announced that its subsidiary, RYAH Medtech Inc., has received ISO 13485:2016/MDSAP and EN ISO 13485:2016 certification for its proprietary Internet of Things (“IoT”)-powered dry herb inhaler (the “RYAH Smart Inhaler”) and software application associated with the device. According to the update, the certification is a regulatory requirement and an international standard that outlines the requirements for a quality management system specific to the medical devices industry. “This is a monumental achievement for RYAH Group Inc. and its subsidiary, RYAH Medtech Inc., as we continue to reimagine plant-based medicine delivery solutions for doctors, clinics and their…

Continue Reading

WednesdayDec 08, 2021 10:35 am

BioMedNewsBreaks – Sixth Wave Innovations Inc.’s (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) AMIPs(TM) Technology to Be Used in Screening Against Omicron Variant

Sixth Wave (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) recently provided an update on its patent-pending Accelerated Molecularly Imprinted Polymer (“AMIPs(TM)”) technology relative to SARS-CoV-2 variants, in particular, B.1.1.529 (“Omicron”). As previously announced, the AMIPS platform was proven capable of detecting all variants of interest tested to date. According to the update, screening against the Omicron variant will commence as soon as virus samples are available at the La Ki Shing Institute of virology, SIXW's testing partner. The identification of yet another variant with suspected properties more transmissible and potentially dangerous than previous generations strongly indicates that COVID-19 will be around…

Continue Reading